Autosomal Dominant Hypocalcemia Type 1 Market to Register a Steady Revenue CAGR … – Press Release

[ad_1]

Newark, New Castle, USA, May 03, 2023 (GLOBE NEWSWIRE) — According to Growth Plus Reports, the global market for autosomal dominant hypocalcemia type 1 was estimated and expect to have a revenue CAGR of 2.7% by 2031.

The global market for autosomal dominant hypocalcemia type 1 was analyzed, and it is expected to rise significantly during the forecast period. An uncommon hereditary condition known as autosomal dominant hypocalcemia type 1 (ADH1) is characterized by unusually low calcium levels in the blood.

Key Takeaways: 

  • The increasing awareness of ADH Type 1 is driving the market revenue share.
  • The increasing development of novel treatment options for rare diseases is driving the demand.
  • The rising awareness of ADH disease and its available treatment options are propelling the market revenue growth.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/autosomal-dominant-hypocalcemia-type-1-market/8695

                Autosomal Dominant Hypocalcemia Type 1 Market Scope

Report Attribute Details
Growth Rate CAGR of 2.7% from 2023 to 2031
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Treatment, End User, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Global Autosomal Dominant Hypocalcemia Type 1 Market: 

  • In December 2022, Encalert’s critical Phase 3 randomized investigation in patients with autosomal dominant hypocalcemia type 1 (CALIBRATE) was started by BridgeBio Pharma. With a primary composite endpoint of calcium concentrations in blood and urine within normal ranges in patients treated with Encaleret vs. SoC, the CALIBRATE study incorporates feedback from patients and regulatory bodies worldwide.

Competitive Landscape

A list of the prominent players operating in the global market for autosomal dominant hypocalcemia type 1 includes: 

  • Shire (Takeda)
  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.

[ad_2]